Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?
- PMID: 39320246
- DOI: 10.23736/S2724-6051.24.06114-7
Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical